BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care
November 15 2022 - 6:00AM
Business Wire
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company, today announced the launch of a new program,
Talk About It: Cancer and Mental Health, designed to elevate the
important intersection of mental health and cancer care to help
improve health outcomes for cancer patients.
Aimed at patients and caregivers, healthcare professionals and
policymakers, Talk About It draws attention to mental health care
as a critical component of quality cancer care. Data shows that up
to a quarter of people living with cancer are also living with
depression, and about half are at risk for clinically significant
anxiety.i Talk About It will feature innovative empowerment
strategies, advance public policy conversations, and inspire
dynamic health equity initiatives to support people throughout
their entire cancer journey.
“At BeiGene, our core value is putting patients first. We not
only want to create impactful medicines for patients globally, but
we also want to truly transform cancer care by supporting the whole
patient - not just treat their disease," said Maia Thrift Perry,
Executive Director, Patient Advocacy & Public Health Policy,
BeiGene. “By bringing visibility to the importance of mental health
and cancer care, this campaign will take an important step toward
improving health outcomes for cancer patients by looking at the
patient holistically when it comes to treatment."
Research Partnership
With guidance from an expert panel, BeiGene kicked off a
collaboration with the Cancer Support Community (CSC) around cancer
and mental health, beginning with a survey of more than 600 US
cancer patients and survivors to learn how cancer affected their
mental health, how that experience was addressed by their care
providers, what barriers they faced, and what resources they found
most helpful.
CSC is a global nonprofit organization that provides free
emotional support, navigation and resources to cancer patients and
their loved ones. As part of their mission, they are dedicated to
inspiring change that improves the cancer experience by engaging in
research that sheds light on the realities of coping with a cancer
diagnosis. Initial results from the survey will be shared in the
coming weeks, with highlights provided at an event for patient
advocates and healthcare providers at the American Society of
Hematology annual meeting in December.
“The good news is that there are treatments for feeling anxious
or depressed,” said CSC’s CEO Debbie Weir. “At CSC, we have been
expanding our support programs and services with new, innovative
offerings along with engaging in meaningful research to help
address these urgent concerns. We are proud to partner with BeiGene
in this urgent work and applaud them for their commitment to
prioritizing the patients’ wellbeing.”
Expert Advisory Panel
As part of BeiGene’s commitment to caring for the whole patient,
the company convened an expert advisory panel comprised of experts
in mental health, oncology, patient advocacy, and behavioral
science to guide the company’s work in supporting the mental health
of those impacted by cancer. Inaugural members include:
- Allison Applebaum, PhD, Associate Attending Psychologist,
Department of Psychiatry & Behavioral Sciences, Memorial Sloan
Kettering Cancer Center
- Elizabeth Archer-Nanda, DNP, APRN; Psychiatric Clinical Nurse
Specialist, Norton Cancer Center Institute, Behavioral Oncology
Program
- Terry Evans, Trained Patient Advocate and Cancer Survivor;
Director, CLL Society Support and Education Network
- Joseph Greer, PhD, Co-Director, Cancer Outcomes Research &
Education Program, Massachusetts General Hospital Cancer
Center
- Heather Honoré Goltz, PhD, LCSW, MEd; Professor of Social Work
& Interim Assistant Department Chair, Department of Criminal
Justice & Social Work, University of Houston-Downtown
- Nicole Peeke, LCSW, ACHP-SW; Social Worker, Adult Hematology/
Hematopoietic Cell Transplantation, City of Hope
- Alexandra Zaleta, PhD, Vice President of Research, Cancer
Support Community
Resource Development
In the coming months, BeiGene will be working collaboratively
with cancer and mental health advocates to mobilize resources and
share a series of patient and provider-centric initiatives designed
to talk about cancer and mental health. These digital and printed
resources for patients, caregivers and health care professionals
will highlight the impact a cancer diagnosis can have on mental
health and provide helpful tools and links to resources offered by
leading patient advocacy organizations and others to help patients
and caregivers navigate their individual cancer journeys and mental
health care needs.
To learn more about Talk About It, visit,
http://www.beigene.com/for-patients/cancer-mental-health/.
About BeiGene
BeiGene is a global biotechnology company that is developing and
commercializing innovative and affordable oncology medicines to
improve treatment outcomes and access for far more patients
worldwide. With a broad portfolio, we are expediting development of
our diverse pipeline of novel therapeutics through our internal
capabilities and collaborations. We are committed to radically
improving access to medicines for far more patients who need them.
Our growing global team of more than 9,000 colleagues spans five
continents, with administrative offices in Beijing, China;
Cambridge, U.S.; and Basel, Switzerland. To learn more about
BeiGene, please visit www.beigene.com and follow us on Twitter at
@BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
BeiGene’s plans, strategies, commitments, aspirations, and goals
for the Talk About It program, and BeiGene’s plans, commitments,
aspirations and goals under the caption “About BeiGene”. Actual
results may differ materially from those indicated in the
forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development or
marketing approval; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials and
marketing approval; BeiGene's ability to achieve commercial success
for its marketed medicines and drug candidates, if approved;
BeiGene's ability to obtain and maintain protection of intellectual
property for its medicines and technology; BeiGene's reliance on
third parties to conduct drug development, manufacturing,
commercialization, and other services; BeiGene’s limited experience
in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development of its drug
candidates and achieve and maintain profitability; the impact of
the COVID-19 pandemic on BeiGene’s clinical development,
regulatory, commercial, manufacturing, and other operations, as
well as those risks more fully discussed in the section entitled
“Risk Factors” in BeiGene’s most recent quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in BeiGene's subsequent filings with the
U.S. Securities and Exchange Commission. All information in this
press release is as of the date of this press release, and BeiGene
undertakes no duty to update such information unless required by
law.
i Krebber et al. (2013). Prevalence of depression in cancer
patients: a meta-analysis of diagnostic interviews and self-report
instruments. Psycho-oncology, 23(2), 121-30; Cancer Support
Community (2022). Spotlight on Mental Health.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221115005412/en/
Investor Kevin Mannix +1-857-302-5189 ir@beigene.com
Media Caryn Marshall +1 862-444-1904 media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024